  
 
 
CLINICAL PROTOCOL  
 
A Phase 2 Open Label Proof -of-Concept Study of HTD1801 in Adult Subjects 
with Primary Biliary Cholangitis (PBC) and an Inadequate Response to 
Standard Therapy  
(PRONTO- PBC)  
 
Protocol HTD1801.PCT013 
IND 136137 
[STUDY_ID_REMOVED] 
 
 
Study Sponsor: HighTide Biopharma Pty. Ltd. 
 Level 13, Citigroup Tower  
 [ADDRESS_951982]  
 Sydney, NSW 2000 
 Australia  
 
 
 
 Date of issue: [ADDRESS_951983]  2021 
 Version number: 4.0 
   
 
CONFIDENTIAL  
 
  

CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 3 TABLE OF CONTENTS  
TABLE OF CONTENTS  .................................................................................................................3  
STATEMENT OF COMPLIANCE  .................................................................................................8  
1. PROTOCOL SUMMARY ............................................................................................9  
1.1. Synopsis ........................................................................................................................9  
1.2. Schema  ........................................................................................................................14  
1.3. Schedule of Activities  .................................................................................................15  
2. INTRODUCTION  ......................................................................................................18  
2.1. Background .................................................................................................................18  
2.1.1.  Primary Biliary Cholangitis  ........................................................................................18  
2.1.2.  HTD1801 ....................................................................................................................18  
2.2. Study Rationale ...........................................................................................................19  
2.3. Risk/Benefit Assessment  ............................................................................................19  
2.3.1.  Known Potential Risks ...............................................................................................19  
2.3.2.  Known Potential Benefits ...........................................................................................19  
2.3.3.  Assessment of Potential Risks and Benefits  ...............................................................19  
3. OBJECTIVES AND ENDPOINTS  ............................................................................20  
4. STUDY DESIGN  .......................................................................................................21  
4.1. Overall Design  ............................................................................................................21  
4.2. Scientific Rationale for Study Design  ........................................................................21  
4.3. Justification for Dose ..................................................................................................21  
4.4. End of Study Definition ..............................................................................................22  
5. STUDY POPULATION  .............................................................................................23  
5.1. Inclusion Criteria  ........................................................................................................23  
5.2. Exclu sion Criteria  .......................................................................................................24  
5.3. Screen Failures  ............................................................................................................25  
6. STUDY INTERVENTION ........................................................................................26  
6.1. Study Intervention Administration .............................................................................26  
6.1.1.  Study Intervention Description ...................................................................................26  
6.1.2.  Dosing and Administration .........................................................................................26  
6.1.3.  Dose Modification ......................................................................................................26  
6.2. Preparation/Handling/Storage/Accountability ............................................................[ADDRESS_951984] Storage and Stability .....................................................................................27  
6.3. Study Intervention Compliance ..................................................................................27  
6.4. Concomitant Therapy .................................................................................................28  
6.4.1.  Permitted Concomitant Medications  ..........................................................................28  
6.4.2.  Prohibited Concomitant Medications  .........................................................................28  
[IP_ADDRESS].  Prohibited medications that are active against PBC  ...................................................28  
[IP_ADDRESS].  Prohibited medications for the treatment of AIH  .......................................................28  
[IP_ADDRESS].  Prohibited medications with potential for drug-drug interaction ...............................28  
7. STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ..................................................................30  
7.1. Decrease in dose of study drug ...................................................................................30  
7.2. Discontinuation of Study Intervention........................................................................30  
7.3. Participant Discontinuation/Withdrawal from the Study  ...........................................30  
7.4. Study Stoppi[INVESTIGATOR_2121]  ..............................................................................................31  
8. STUDY PROCEDURES AND EVALUATIONS  .....................................................32  
8.1. Pre-screening (Days -56 to -28) ALP .........................................................................32  
8.2. Screening (Days -28 to -1) ..........................................................................................32  
8.3. Baseline/Day 0  ............................................................................................................33  
8.4. Week 2 and Week 4 Visits (±3 days) .........................................................................34  
8.5. Week 6 Visit (±3 days) ...............................................................................................34  
8.6. Week 8 Visit (±3 days) ...............................................................................................35  
8.7. Week 12 Visit (±3 days) .............................................................................................35  
8.8. Week 16 Visit (±5 days) .............................................................................................36  
8.9. Early Termination Visit ..............................................................................................37  
9. STUDY ASSESSMENTS AND PROCEDURES  ......................................................38  
9.1. Efficacy Assessments  .................................................................................................38  
9.1.1.  Serum Alkaline Phosphatase Endpoints .....................................................................38  
9.1.2.  Secondary Efficacy Endpoints ....................................................................................38  
9.2. Safety and Other Assessments  ....................................................................................38  
9.2.1.  Demographics and Medical History ...........................................................................38  
9.2.2.  Adverse Events  ...........................................................................................................38  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 5 9.2.3.  Physi cal Examinations  ................................................................................................38  
9.2.4.  Vital Signs, Height, and Weight .................................................................................39  
9.2.5.  Electrocardiograms  .....................................................................................................39  
9.2.6.  Safety Related Laboratory Assessments  .....................................................................39  
9.2.7.  GLOBE Score  .............................................................................................................40  
9.2.8.  Pruritus VAS  ...............................................................................................................40  
9.2.9.  Pharmacokinetic (PK) sub -study ................................................................................41  
9.3. Adverse Events and Serious Adverse Events .............................................................41  
9.3.1.  Definition of Adverse Event (AE) ..............................................................................41  
9.3.2.  Definition of Serious Adverse Event (SAE) ...............................................................42  
9.3.3.  Classification of an Adverse Event .............................................................................43  
[IP_ADDRESS].  Severity of Event ........................................................................................................43  
[IP_ADDRESS].  Relationship to Study Intervention .............................................................................44  
[IP_ADDRESS].  Expectedness  ...............................................................................................................[ADDRESS_951985]  ...........................................................................................47  
[IP_ADDRESS].  Gastrointestinal Event  .................................................................................................47  
[IP_ADDRESS].  Treatment Failure due to HTD1801 Dose Reduction .................................................47  
[IP_ADDRESS].  Reporting of Pregnancy ..............................................................................................47  
10. DRUG- INDUCED LIVER INJURY (DILI) MONITORING AND 
STOPPI[INVESTIGATOR_16442] ....................................................................................................[ADDRESS_951986] .....................................................53  
11.2.  Operational Contingencies related to COVID- 19 Pandemic  ......................................53  
12. STATISTICAL CONSIDERATIONS  .......................................................................54  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 6 12.1.  Statistical Hypotheses  .................................................................................................54  
12.2.  Sample Size Determination  ........................................................................................54  
12.3.  Populations for Analyses ............................................................................................54  
12.4.  Statistical Analyses  .....................................................................................................54  
12.4.1.  General Approach  .......................................................................................................54  
12.4.2.  Analysis of the Primary Efficacy Endpoint(s) ............................................................55  
12.4.3.  Analysis of the Secondary Endpoint(s) ......................................................................55  
12.4.4.  Safety Analyses  ..........................................................................................................55  
12.4.5.  Pharamacokinetic Analyses  ........................................................................................55  
12.4.6.  Baseline Descriptive Statistics  ....................................................................................55  
12.4.7.  Planned Interim Analyses ...........................................................................................55  
13. STUDY ADMINISTRATION  ...................................................................................56  
13.1.  Informed Consent and Authorization For Use and Disclosure of Protected 
Health Information ......................................................................................................56  
13.2.  Study Discontinuation and Closure ............................................................................56  
13.3.  Study Documentation .................................................................................................56  
13.3.1.  Investigator Information  .............................................................................................56  
13.3.2.  Investigator’s Study Files ...........................................................................................[ADDRESS_951987] OF TABLES  
Table 1  Schedule of Events .....................................................................................................15  
Table 2:  Prohibited Medications with potential for drug-drug interaction ...............................29  
Table 3  Laboratory Analytes ...................................................................................................40  
Table 4  Classification of Adverse Events (AEs) by [CONTACT_86945] ..................................................44  
Table 5  Assessment of Causality of AEs .................................................................................45  
Table 6  Timeline for Reporting SAEs .....................................................................................46  
Table 7:  Liver Monitoring Procedure – For Subjects with Normal or Near Normal 
Baseline ALT ( ≤60 U/L) ...........................................................................................49  
Table 8:  Liver Monitoring Procedure – For Subjects with Calculated Baseline ALT 
>60 U/L (Elevated ALT)  ............................................................................................51  
 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 8 STATEMENT OF COMPLIANCE  
The trial will be conducted in accordance with International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) and applicable [LOCATION_002] (US) Code of Federal Regulations 
(CFR) applicable to clinical stu dies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR 
Part 312, and/or 21 CFR Part 812). The Principal Investigator [INVESTIGATOR_7433], 
or changes to the protocol will take place without prior agreement from the Investigational New 
Drug (IND) sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All 
personnel involved in the conduct of this study have completed Human Subjects Protection and 
ICH GCP Training. 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the IRB for review and approval. Approval of both the protocol and the consent 
form must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_3484]. All 
changes to the consent form will be IRB approved; a determination will be made regarding 
whether a new consent needs to be obtained from participants who provided consent, using a previously approved consent form. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 9 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Name [CONTACT_61486]:  HighTide Biopharma Pty. Ltd. 
Name [CONTACT_23360]:  HTD1801 Tablets 
Name(s) of active ingredient(s): Berberine Ursodeoxycholate  
Title of study: A Phase 2 Open Label Pro of-of- Concep t Study of HTD1801 in Adult Subjects with 
Primary Biliary Cholangitis (PBC) and an Inadequate Response to Standard Therapy (PRONTO- PBC)  
Investigator(s): Multicenter  
Number of sites:   Up to 20 
Study periods:  
Pre-screening:  Up to 28 days 
Screening:  Up to 28 days 
Open -label treatment:  12 weeks  
Follow-up :  [ADDRESS_951988] (IP)  Phase of development: 2 
Objectives  Endpoints  
Primary Objective:  
To evaluate the effects of HTD1801 on 
serum alkaline phosphatase (ALP) in adult subjects with PBC who have experienced an inadequate response to 
standard therapy. Inadequate response is defined as ALP  
≥1.5 × ULN despi[INVESTIGATOR_701309] 6 months. Primary Endpoint:  
• Percent change in ALP at Week 1 2 compared to 
Baseline.  
Additional ALP Secondary Endpoints:  
• Absolute change in ALP at Week 12 compared to 
Baseline  
• Proportion of subjects who have ≥20% decrease in ALP from Baseline to Week 12 
• Proportion of subjects who have ≥40% decrease in ALP from Baseline to Week 12 
• The proportion of subjec ts who normalize ALP at 
Week 12  
Secondary Objectives:  Secondary Endpoints:  
To evaluate the effects of HTD1801 on 
serum markers of cholestasis  • Change in total bilirubin from Baseline to Week 12  
• Change in serum gamma -glutamyl transferase 
(GGT) between Baseline and Week 12 
• Change in ALT from Baseline to Week12 
• Change in AST from Baseline to Week 12 
To evaluate the effects of HTD1801 on 
serum lipi[INVESTIGATOR_805]  • Change in serum cholesterol (total and LDL) and 
triglyceride levels between Baseline and Week 12  
To evaluate the effects of HTD1801 on 
serum markers of inflammation  • Change  in inflammatory serum markers including 
fibrinogen, CRP, Haptoglobin, ELF and serum 
immunoglobulins between Baseline and Week 12  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 10 To evaluate the safety and tolerability 
of HTD1801 over 12 weeks of 
treatment in adult subjects with PBC  • Change in GLOBE scor e between Baseline and 
Week 12  
• Change in prurit us as measured by [CONTACT_701327] (VAS) between Baseline and Week 12  
• Adverse events and changes in physical 
examination, vital signs, and clinical laboratory 
values 
To evaluate the pharmacokineti c profile 
of HTD1801in a subset o f subjects 
participating in this study  Descriptive statistics on plasma concentrations of 
measured analytes for berberine and UDCA and its 
conjugates  
 
Study Design: A single arm, 12- week open -label study with follow -up [ADDRESS_951989] dose of IP. 
Upon confirmation of eligibility, subjects will be enrolled and will receive HTD1801 1000 mg BID for 12 weeks.  
Number of subjects: Up to [ADDRESS_951990] may be enrolled.  
Inclusion criteria:  
1. Male or female between [ADDRESS_951991] a clinical diagnosis of PBC as confirmed by [CONTACT_701328] A merican 
Association for the Study of Liver Diseases ( AASLD) Practice Guideline confirmed by [CONTACT_701329]:  
a) Biochemical evidence of cholestasis with elevation of ALP activity  
b) Presence of antimitochondrial antibody ( AMA ) 
c) Histopathologic evidence of nonsuppurative cholangitis and destruction of small or medium-sized bile ducts if biopsy performed 
Note: historical AMA and liver biopsy data may be used but must be recorded in source 
documentation. 
3. Has been taking a stable, adequate dose ( at minimum 13mg/kg/day) of UDCA for at least 6 
months, with a  serum ALP of  ≥1.5 × ULN  
4. Has two consecutive values of ALP >1.5x ULN (historical and screening values) of which the 
second ALP value must not be down trending relative to the first ALP value  
a. If the historical ALP value was obtained more than [ADDRESS_951992] of care, a more recent historical value should be obtained as a part of a pre -screening 
visit.  If this more recent value is ≥1.5 × ULN, the subject may be scheduled for full screen ing as 
soon as [ADDRESS_951993] be >1.5x ULN.  
b. If the historical ALP value was obtai ned less than [ADDRESS_951994] be ≥1.[ADDRESS_951995].  
c. If the screening ALP value is more than ≥30% lower than the historical value obtained 
as part of standard of care, the subject will not qualify for enrollment  but may be re-
screened  as soon as 4 weeks later .  If on re -screening the ALP value continues to be 
>30% lower, the subject will not be eligible to be  in the study.  Because  there may be 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_951996] trends of more than 30% should take this into account  
5. Be willing to discontinue UDCA the day prior to the start of IP dosing 
6. Be willing to discontinue the use of berberine supplements or berberine  herbal products the day 
prior to the start of IP dosing  
7. If the subject is taking c holestyramine or other bile acid sequestrant for prurit us, the subject must 
be on a stable dose and taking it no more than once a day for at least [ADDRESS_951997] 
appropriate documentation 
9. Be able to understand and sign a written or electronic informed consent form (ICF) 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 12 Exclusion criteria:  
1. Uncontrolled concomitant autoimmune hepatitis (AIH). Subject should be on no more 
than 5 mg per day of prednisone (or equivalent dose for other corticosteroids) or no 
more than 150 mg per day of azathioprine at stable doses and serum ALT should be ≤ 5 × UL N.  Use of medications other than prednisone or azathioprine for the treatment 
of AIH is prohibited (e.g., Mycophenolate).  Stable use of immunosuppressives for 
other indications may be permitted (see below).  Enrollment of subjects with 
controlled AIH wil l be limited to a total of 5 subjects.  
2. Other plausible reasons for elevations in serum alkaline phosphatase such as drug -
induced liver injury, concomitant cholestatic liver disease or bone disease. 
3. History of alcohol or substance abuse  
4. Prior liver transpla ntation  or currently listed for liver transplantation  
5. History  of chronic viral hepatitis, types B or C  
6. Platelet count <150,000/mm
3, albumin <3.0 g/dL, International Normalized Ratio 
(INR) >1.2, or a history of ascites, or encephalopathy, or history of variceal bleeding  
7. Total bilirubin >1.3 mg/dL unless subject has Gilbert ’s Syndrome.  If subject has 
increased total bilirubin due to Gilbert’s Syndrome, then direct bilirubin should be <0.3 mg/dL. 
8. Hemoglobin <10 g/dL for males or females  
9. Serum TSH level <0 .1 or >10 u/mL (subject may be re- screened if hyper- or 
hypothyroidism has been corrected)  
10. Renal impairment with eGFR <60ml/min /1.73 m
^2 (CKD stages 3, 4 or 5) 
11. Human immunodeficiency virus (HIV) -1 or HIV-2 infection by [CONTACT_969] 
12. Glucose-6-phosphate dehydroge nase (G6PD) deficiency ,  a screening assay will be 
performed.  If serum level is below normal, clinical evaluation and further testing may 
be needed to confirm a diagnosis of G6PD deficiency.  
 
13. History of malignancy within the past 2 years or ongoing malignancy other than basal 
cell carcinoma, or resected noninvasive cutaneous squamous cell carcinoma  
14. Active, serious infections that require parenteral antibiotic or antifungal therapy 
within 30 days prior to Screening 
15. Major surgical procedure within 30 days of Screening or prior solid organ transplantation  
16. Females who are pregnant or breastfeeding  
17. Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic 
agents, and immune-modulating agents (such as interleukins, interferons).  Chronic, 
stable use of immunosuppressive medication may be allowed with medical monitor 
approval 
18. Allergy to the clinical trial material or its components  
19. Having received any experimental medications within [ADDRESS_951998] day of IP dosing  
21. Use of obeticholic acid (OCA) within [ADDRESS_951999], dose, and mode of administration:   
HTD1801:  1000 mg administered as tablets twice daily with food  
Reference therapy, dose and mode of administratio n:  N/A 
Duration of treatment: Up to  12 weeks  
Criteria for Evaluation: 
Efficacy Evaluation Efficacy endpoints will be evaluated with descriptive statistics to include 95% confidence intervals. 
Testing will be used. For the primary endpoint a one sample t -test against a null hypothesis of no 
change, will be used with a 5% one-sided alpha level. The safety population will include all treated subjects and the efficacy population will include all treated subjects with at least one post dose ALP 
assess ment. Baseline will be assigned to the last available assessment prior to the start of treatment.  
Safety Evaluation 
Adverse events and changes in clinical laboratory assessments will be used to evaluate safety and 
tolerability. Safety data will be summariz ed using descriptive analysis. 
Sample Size:  
A sample size of 30  subjects provides ≥90% power for the primary endpoint assuming a mean percent 
reduction in ALP of 15% and a SD of 25%. Power calculations use a 5% one sided alpha and a t- test. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 14 1.2. Schema  
 
 
Optional 
Pre-
Screening 
for ALP  Screening  Baseline  
Initiate IP 
Dosing  IP Dosing  
HTD1801 1000 mg BID Follow- Up 
End of 
Study  
Day -56 to 
Day -28 Day -28 to 
Day -1 Day 0  Week 2  
Day 14 
±3 days Week 4  
Day 28 
±3 days Week 6  
Day 42 
±3 days Week 8  
Day 56 
±3 days Week 12  
Day 84 
±3 days Week 16  
Day 112 
±5 days 
PK Sampling:  
-30 minutes 
prior to dosing, 
4 hours ±30 
minutes and  
8 hours ±[ADDRESS_952000] 6 subjects  
  PK Sampling:  
-30 minutes 
prior to dosing, 
4 hours ±30 
minutes and  
8 hours ±[ADDRESS_952001] 6 subjects  
  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 15 1.3. Schedule of Activities  
Table 1 Schedule of Events  
 Optional  
Pre-screeing  Screening  Baseline  Wk 2  Wk 4  Wk 6  Wk 8  Wk12 ETh Wk 16 Follow -
up 
Visit Day  -56 to -28 -28 to -1 0 14 28 42 56 84 NA +28d (Day 112)  
Procedure / Window   - - ±3d ±3d ±3d ±3d ±3d ±5d 
Clinic visit  X X X Xd Xd X Xd X Xd Xi 
Informed consent  X Xj         
Eligibility criteria   X Xa        
Demographics   X         
Medical history   X Xa        
Assign subject ID# X X         
Dispense study drug    X   X     
Return study drug       Xb  Xb Xb  
Study discharge          X X 
Complete physical examination   X         
Targeted physical examination c   Xc   Xc  Xc Xc Xc 
Vital signs   X X   X  X X X 
Weight   X X   X  X X X 
Height   X         
BMI (calculated within EDC)   X         
ECG   X      X X  
Serum chemistry panel including 
GGT  X X X Xd Xd X Xd X Xd Xd 
Lipid panel (triglycerides, HDL -
c, LDL -c, and total cholesterol)   Xi Xi   Xi  Xi Xi  
CBC with differential (no smear)   X X   X  X X  
INR  X    X  X X  
Fibrinogen   X X   X  X X  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 16  Optional  
Pre-screeing  Screening  Baseline  Wk 2  Wk 4  Wk 6  Wk 8  Wk12 ETh Wk 16 Follow -
up 
Visit Day  -56 to -28 -28 to -1 0 14 28 42 56 84 
NA +28d (Day 112)  
Procedure / Window   - - ±3d ±3d ±3d ±3d ±3d ±5d 
CRP   X X   X  X X  
Haptoglobulin   X X   X  X X  
ELF  X X   X  X X  
G6PD   X         
IgM  X X   X  X X  
IgG  X X   X  X X  
Bile acid panele   Xe   Xe  Xe Xe  
AMA   X         
ANA   X         
TSH   X         
FSHf  Xf         
PK blood drawg      Xg  Xg   
Urine Pregnancy Test    Xk     Xk Xk  
GLOBE Score    Xl   Xl  Xl Xl  
Pruritus VAS  X X   X  X X  
Adverse event monitoring    Xa X X X X X X X 
Prior and concomitant 
medications   X Xa X X X X X X X 
Abbreviations: AMA = antimitochondrial antibody; ANA = antinuclear antibody; BMI = body mass index; CBC = complete blood count; CRP = C- reactive 
protein; ECG = electrocardiogram; EDC = electronic data capture; ELF = enhanced liver fibrosis; FSH = follicle stimulating hormone; G6PD = glucose -6-
phosphate dehydrogenase; GGT = gamma -glutamyl transferase; HDL -c = high -density lipoprotein cholesterol; IgG = immunoglobulin G; IgM = 
immunoglobulin M; INR = international normalized ratio; LDL -c = low -density lipoprotein cholesterol; PBC = primary biliary cholangitis; TSH = thyroid 
stimulating hormone; VAS = visual analogue scale  
a Confirm continued eligibility  
b IP return and reconciliation  
c Targeted PE to include assessment of only those findings that were abnormal  at Screening/Baseline visit and any new symptoms exhibited or volunteered by 
[CONTACT_1130]  
d Optional “in-h ome” blood draw for COVID -19 contingency  measures   
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 17 e Bile Acid Panel only for those subjects for whom a sample was obtained at Baseline  
f Female subjects only, To confirm menopausal status  
g Drawn -30 minutes prior to dosing at Week 6 and Week 12; drawn 4 hours (±30 minutes) and 8 hours (±30 minutes) post investigational study drug dosing at Week [ADDRESS_952002] unsweetened, clear coffee, tea or water but no food after supper the evening before  
j If consent not obtained prior to optional pre -screening visit  
k Only for women of childbearing potential  
l GLOBE score calculated by [CONTACT_701330]. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 18 2. INTRODUCTION 
2.1. Background  
2.1.1. Primary Biliary Cholangitis 
Primary biliary cholangitis (PBC) , formerly known as primary biliary cirrhosis, is a chr onic, 
slowly progressive autoimmune liver disease. PBC mainly affects women (90%) and, typi[INVESTIGATOR_897], 
is diagnosed between the ages of 35 - 60. It is characterized by [CONTACT_701331], accompanied by [CONTACT_11674] (excess fibrous connective tissue) and eventually cirrhosis (extensive scarring of the liver). Another key feature is the presence of specific anti-mitochondrial antibodies (AMA) in the blood in over 90% of the patients.  
PBC is a relatively rare disease and occurs worldwide. The incidence and prevalence in various 
countries and regions differ considerably and have been reported to vary from 0.[ADDRESS_952003] common symptoms are fatigue and itching. 
Treatment with ursodeoxycholic acid (UDCA) is standard for PBC and can improve liver 
function tests and slow the progression of disease. UDCA was first approved in 1997 in the US 
for the treatment of PBC ( URSO 250 and URSO Forte Prescribing Information 2013). In a study 
of 180 patients with PBC, UDCA at doses of 13 to 15 mg/kg/day was shown to improve liver 
biochemistry, delay the progression of liver disease, and prevent the need for liver 
transplantation relative to placebo treatment ( Levy  2003, Lindor 1996). The results of another 
randomized, double-blind, placebo-controlled trial enrolling 103 patients with PBC showed that 
13 to 15 mg/kg/day UDCA was associated with a 5-fold lower progression rate from early stage 
disease to extensive fibrosis or cirrhosis ( Corpechot 2000).  Up to 40% of PBC patients have an 
inadequate response to UDCA and may continue to have disease progression. Obeticholic acid 
(OCALIVA, OCA), a farnesoid X receptor (FXR) agonist, is indicated for the trea tment of PBC 
in combination with UDCA in adults with an inadequate response to UDCA, or as monotherapy 
in adults unable to tolerate UDCA ( OCALIVA Prescribing Information 2020 ). The addition of 
OCA to UDCA can significantly improve serum ALP , GGT, ALT  and total bilirubin, which are 
markers of clinical outcome in PBC  (Bahar  2018;  Hirschfield  2015).  
2.1.2. HTD1801  
HTD1801 is a novel salt formed between berberine (BBR) and ursodeoxycholic acid (UDCA) 
with a stoichiometry of 1:1. HTD1801 is currently being developed as an oral treatment for PBC, 
primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). HTD1801 is expected to dissociate into BBR salt and UDCA after oral administration . Due to the different 
mechanisms of the two products, at least an additive, and possibly an additive or synergistic effect may occur when they are administered together in the form of HTD1801. This study will evaluate HTD1801 in adult subjects with PB C by [CONTACT_701332] 
(ALP) over [ADDRESS_952004] igator’s Brochure.  
2.2. Study Rationale  
HTD1801 is a salt of ursodeoxycholic acid ( UDCA) and berberine ( BBR) . UDCA has been the 
mainstay of primary biliary cholangitis (PBC) for many years and has dramatically improved the 
prognosis of the disease. UDCA is now registered around the world for the first- line treatment of 
the disease. Unfortunately, around 40 to 50% of PBC patients do not respond to UDCA or do not maintain an adequate response to UDCA. An inadequate response to UDCA is defined as a 
persistence of a biochemical cholestatic syndrome and is generally expressed as a persistent 
increase of serum alkaline phosphatase ( ALP ) above 1.67 times the upper limit of normal for the 
laboratory performing the analysis. Unfortunately, around 50% of PBC patients who a re 
incomplete responders to UDCA do not respond to the addition of obeticholic acid. In addition, treatment with obeticholic acid may induce or exacerbate pruritus, a symptom frequently affecting PBC patients, and thus may lead to treatment discontinuation. Hence, there is still an unmet medical need in PBC patient s. 
The addition of BBR to UDCA, as a salt, in HTD1801 could deliver a benefit to PBC patients who are inadequate responders to UDCA alone. While BBR alone has not been studied in PBC, 
non-clinical  data obtained with HTD1801 support studying the drug in PBC. In a rat model of 
cholestasis and liver inflammation, the bile duct ligation model, HTD1801 was effective in 
decreasing liver inflammation and necrosis, and improving bile duct health by [CONTACT_701333]. In addition, HTD1801 
treatment was associated with an improvement in serum markers of cholestasis (ALP and GGT). In this model, UDCA generally gives mixed results and thus the improvement could be rationalized to come from the association of BBR and UDCA in HTD1801.  
2.3. Risk/Benefit Assessment  
2.3.1. Known Potential Risks  
HTD1801 has been evaluated in a clinical study in patients with NASH and type II diabetes. In 
that study, HTD1801 was well tolerated at [ADDRESS_952005] 
common treatment -related AEs were gastrointestinal disorders ( diarrhea and nausea), which 
occurred more frequently in the HTD1801 [ADDRESS_952006] potential benefit of HTD1801 in 
subjects with PBC.  
2.3.3. Assessment of Potential Risks and Benefits  
The known and potential risks anticipated with HTD1801 appear justified by [CONTACT_701334]. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 20 3. OBJECTIVES AND ENDPOINTS  
Objectives  Endpoints  
Primary Objective:  
To evaluate the effects of 
HTD1801 on serum alkaline phosphatase (ALP) in adult subjects with PBC who have experienced an inadequate response to standard therapy. 
Inadequate response is defined as ALP ≥1.5 × ULN despi[INVESTIGATOR_701309] 6 months Primary Endpoint:  
• Percent change in ALP at Week 1 2 compared to 
Baseline.  
Additional ALP Secondary Endpoints:  
• Absolute change in ALP at Week 12 compared to 
Baseline  
• Proportion of subjects who have ≥20% decrease in ALP from Baseline to Week 12  
• Proportion of subjects who have ≥40% decrease in ALP from Baseline to Week 12  
• The proportion of subjects who normalize ALP at Week 
12 
Secondary Objectives:  Secondary Endpoints:  
To evaluate the effects of 
HTD1801 on serum markers of 
cholestasis  • Change  in total bilirubin from Baseline to Week 12  
• Change in serum gamma -glutamyl transferase (GGT) 
between Baseline and Week 12 
• Change in ALT fr om Baseline to Week12  
• Change in AST from Baseline to Week 1 2 
To evaluate the effects of 
HTD1801 on serum lipi[INVESTIGATOR_805]  • Change  in serum cholesterol (total and LDL) and 
triglyceride levels between Baseline and Week 12  
To evaluate the effects of 
HTD1801 on serum markers of 
inflammation  •  Change in inflammatory serum markers including 
fibrinogen, CRP, Haptoglobin, ELF and serum 
immu noglobulins between Baseline and Week 12  
To evaluate the safety and 
tolerability of HTD1801 over 12 
weeks of treatment in adult subjects with PBC  • Change in GLOBE score between Baseline and Week 12  
• Change in prurit us as measured by [CONTACT_701335] (VAS) between Baseline and Week 12  
• Adverse events and changes in physical examination, 
vital signs, and clinical laboratory values  
To evaluate the pharmacokinetic 
profile of HTD1801in a subset of 
subjects participating in this study  • Descripti ve statistics on plasma concentrations of 
measured analytes for berberine and UDCA  and its 
conjugates 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952007] therapy. 
Inadequate response is defined as ALP ≥1.5 × ULN despi[INVESTIGATOR_701310] 6 months. Up to 30 subjects may be enrolled at up to 20 participating clinical sites.  
Subjects may be pre-screened 28 to 56 days prior to the screening day visit using the central 
laboratory to confirm that their alkaline phosphatase is ≥1.[ADDRESS_952008] dose of study drug. The Week 2, 4, and 8 visits may be performed remotely (home visits).  
4.2. Scientific Rationale for Study Design  
This is a  single arm,  open-label proof-of-concept study. All subjects will receive active study 
drug treatment. This study design is appropriate for a proof-of-concept study for an intervention 
in a new indication for PBC patients where the laboratory markers do not improve spontaneously 
and over time, are expected to get worse. Hence, seeing improvements, even without a control arm, is sufficient to meet the scientific goal of providing an indication of efficacy while also providing safety data. 
4.3. Justification for Dose  
The justification for the dose of HTD1801 selected for this study is based on HighTide’s experience with this agent in previous clinical trials in other diseases.  A Phase 1b/2a study was 
conducted in subjects with hyperlipi[INVESTIGATOR_83281] a Phase 2 study was conducted in subjects with 
NASH. Even though these are different patient populations from the population to be evaluated 
in study HTD1801.PCT013, the observations from these studies help inform dose selection in PBC.  
In the Phase 1b/2a study (study HTD1801.PCT004), in patients with hyperlipi[INVESTIGATOR_035], multiple ascending doses of HTD1801 500 mg, 1000 mg and 2000 mg per day were evaluated for up to 28 days. In this study HTD1801 2000 mg per day was effective in lowering serum cholesterol levels by [CONTACT_3450] 11% (Di Bisceglie 2020). 
In the Phase 2 study in NASH (Study HTD1801.PCT012), two doses of HTD1801 were 
evaluated – 1000 mg per day and 2000 mg per day both given for 18 weeks. The dose of 2000 
mg per day was effective in decreasing liver fat content and improving glycemic control, more so than the 1000 mg per day dose (Harrison et al. 2020).  
In this same study, it was found that the relationship between decrease in liver fat content and 
body weight at baseline revealed no meaningful trends, implying that the pharmacodynamic 
changes associated with HTD1801 are relatively unaffected by [CONTACT_18694] (see Figure 1; Study # HTD1801.PCT012) (Harrison et al. 2020).  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952009] a favorable safety profile; gastrointestinal (GI) events were the mo st 
common adverse event in these studies; in the study in NASH 12% of subjects who received 1000 mg BID administration discontinued study drug due to GI events whereas there were no discontinuations due to these events in the study in PSC. 
For the reasons cited above, the dosage of HTD1801 selected for this study (1000mg BID) is 
considered appropriate for use in the study population. 
4.4. End of Study Definition  
A participant is considered to have completed the study if he or she has completed all phases of 
the study including the last visit or the last scheduled procedure shown in the Schedule of 
Activities, Section 1.3. 
The end of the study is defined as the date of completion of the last visit or procedure shown in 
the Schedule of Activities in the trial globally for the last subject in the study.  
The end of enrollment if less than [ADDRESS_952010] meet all of the following 
criteria:  
1. Male or female between 18 and 75 years of age  
2. Has a clinical diagnosis of PBC as confirmed by [CONTACT_701336] ( AASLD ) Practice Guideline 
(Lindor 2019) confirmed by [CONTACT_701337]: 
a. Biochemical evidence of cholestasis with elevation of ALP activity  
b. Presence of antimitochondrial antibody ( AMA) 
c. Histopathologic evidence of nonsuppurative cholangitis and destruction of small or 
medium- sized  bile ducts if biopsy performed 
Note: historical AMA and liver biopsy data may be used, but must be recorded in source 
documentation. 
3. Has been taking a stable, adequate dose ( at minimum 13 mg/kg/day) of UDCA for at least 
6 months with a serum ALP of  ≥1.5 × ULN.  
4. Has two consecutive values of ALP ≥1.5 × ULN (historical and screening values) of which the second ALP value must not be down trending relative to the first ALP value  
a. If the historical ALP value was obtained more than [ADDRESS_952011] of care , a more recent historical value should be obtained either using 
the local laboratory or alternatively, a chemistry sample can be submitted to the central laboratory as a part of 
an optional pre -screening visit.  If this more recent valu e 
is ≥1.5 × ULN, the subject may be scheduled for a full screen ing visit as soon as [ADDRESS_952012] be ≥1.[ADDRESS_952013] be ≥1.[ADDRESS_952014]. 
c. If the screening ALP value is  more than ≥30% lower than the historical value 
obtained as part of standard of care, the subject will not qualify for enrollment but 
may be re -screened  as soon as 4 weeks  later .  If on re -screening the ALP value 
continues to be >30% lower, the subject will not be included in the study. Because there may be considerable variability in the reference range for ALP obtained for the historical value, the estimation of downward trends of more than 30% should take this 
into account. 
5. Be willing to discontinue UDCA the day prior to the start of IP dosing. 
6. Be willing to discontinue the use of berberine 
supplements or berberine herbal products the 
day prior to the start of IP dosing  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952015] appropriate documentation 
9. Be able to understand and sign a written or electronic informed consent form (ICF) 
5.2. Exclusion Criteria  
An individual who me ets any of the following criteria will be excluded from participation in the 
study. 
1. Uncontrolled concomitant autoimmune hepatitis (AIH). Subject should be on no more 
than 5 mg per day of prednisone (or equivalent dose for other corticosteroids) or no more 
than 150 mg per day of azathioprine at stable doses and serum ALT should be ≤5 × ULN.  
Use of medications other than prednisone or azathioprine for the treatment of AIH is prohibited 
(e.g., Mycophenolate). Stable use of immunosuppressives for other indications may be permitted 
(see below).  Enrollment of subjects with controlled AIH will be limited to a total of 5 subjects.  
2. Other plausible reasons for elevations in serum alkaline phosphatase such as drug-
induced liver injury, concomitant cholestatic liver disease or bone disease. 
3. History of alcohol or substance abuse 
4. Prior liver transplantation  or currently listed for liver transplantation  
5. Presence of chronic viral hepatitis, types B or C.  
6. Platelet count <150,000/mm3, albumin <3.0 g/dL, International Normalized Ratio (INR) 
>1.2, or a history of ascites, or encephalopathy, or history of esophageal variceal bleeding 
7. Total bilirubin >1.3 mg/dL unless subject has Gilbert ’s Syndrome.  If subject has 
increased tot al bilirubin due to Gilbert’s Syndrome, then direct bilirubin should be <0.3 
mg/dL. 
8. Hemoglobin <10 g/dL for males or females 
9. Serum TSH level <0.1 or >10 u/mL (subject may be re- screened if hyper - or 
hypothyroidism has been corrected) 
10. Renal impairment with eGFR <60ml/min /1.73 m ^2  (CKD stages 3, 4 or 5) 
11. Human immunodeficiency virus (HIV)- 1 or HIV -2 infection by [CONTACT_969] 
12. Glucose-6-phosphate dehydrogenase (G6PD) deficiency.  A screening assay will be 
performed.  If serum level is below normal, clinical evaluation and further testing may be 
needed to confirm a diagnosis of G6PD deficiency. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952016] 2 years or ongoing malignancy other than basal 
cell carcinoma, or resected noninvasive cutaneous squamous cell carcinoma 
14. Active, serious infections that require parenteral antibiotic or antifungal therapy within 30 days prior to Screening 
15. Major surgical procedure within 30 days of Screening or prior solid organ transplantation 
16. Females who are pregnant or breastfeeding  
17. Current or anticipated treatment with radiation therapy, cytotoxic chemotherapeutic 
agents , and immune-modulating agents (such as interleukins, interferons).  Chronic, 
stable use of immunosuppressive medications may be allowed with medical monitor approval 
18. Allergy to  the clinical trial material or its components  
19. Having received any experimental medications within [ADDRESS_952017] day of IP dosing 
21. Use of obeticholic acid (OCA) within [ADDRESS_952018] fails to meet eligibility criteria upon rescreen, he/she will remain ineligible for the study.  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 26 6. STUDY INTERVENTION  
6.1. Study Intervention Administration  
6.1.1. Study Intervention Description 
The HTD1801 drug substance, berberine ursodeoxycholate, is the salt formed between BBR and 
UDCA with a stoichiometry of 1:[ADDRESS_952019] is a film coated tablet containing 
250 mg of berberine ursodeoxycholate. 
6.1.2. Dosing and Administration  
HTD1801 tablets (1000 mg dose) are administered twice daily (BID) with food.  Subjects are 
instructed to take the entire contents of 1 pouch of study drug each morning and each evening 
with water and food (e.g., meal or snack). Each pouch will contain [ADDRESS_952020] not be re dispensed to subjects. 
6.1.3. Dose Modification 
In the event of gastrointestinal (GI) discomfort as outlined in Section 9.3.8 at the starting dose of 
1000 mg BID (4 tablets in the morning after a meal and 4 tablets in the evening after a meal ), 
dose reduction is allowed per the following guidelines: 
• For GI symptoms that are difficult for the subject to tolerate, decrease dose to 1500 mg per day (3 tablets in the morning after a meal and 3 tablets in the evening after a meal ) for [ADDRESS_952021] should stay on that dose and 
not attempt to go back up to full dose. 
• If symptoms persist after 1 week at the lower 1500 mg per day dose, decrease dose to 
1000 mg per day (2 tablets in the morning after a meal and 2 tablets in the evening 
after a meal ) for [ADDRESS_952022] should stay on that dose and 
not attempt to go back up to full dose. 
• If symptoms persist after [ADDRESS_952023] their dose of study drug decreased will be monitored closely with serum 
ALP, aminotransferases and bilirubin levels being measured every 2 to 4 weeks.  Elevations in 
ALP or bilirubin will be promptly recognized by [CONTACT_7880] [INVESTIGATOR_701311].  If ALP levels after having been lowered on initial treatment go back 
up to baseline or higher on two subsequent occ asions (baseline being the average of the historical 
value and the value at screening). , the subject will be deemed to be a treatment failure and will 
discontinue investigational study drug (see Section  7.3).  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 27 6.2. Preparation/Handling/Storage/Accountability 
6.2.1. Acquisition and Accountability  
HTD1801 [ADDRESS_952024]  is a white to off -white film-coated tablet containing 250 mg of 
HTD1801.  
Inactive excipi[INVESTIGATOR_138627] a silicified microcrystalline cellulose (SMCC90), sodium 
carboxymethyl starch, and magnesium stearate. The tablets are coated with Opadry
® immediate 
release film (product grade: 03A18375), resulting in an average gain of 15 mg/tablet. The 
qualities of all excipi[INVESTIGATOR_701312]. 
HTD1801 tablets are packaged into polyethylene terepht halate/aluminum foil/polyethylene 
(PET/AL/PE) pouches. Each pouch will contain 4 HTD1801 250 mg tablets and be affixed with 
a single-panel label that will describe the following information at a minimum: study drug, dose, 
kit number, Sponsor name, instructions for storage between 36°F and 46°F (2°C and 8°C), and 
includes the statements “Caution: New Drug - Limited by [CONTACT_120906]” and “Keep out of reach of children.” 
An adequate supply of pouches will be placed into kits packaged for weekly use, and each 
subject will receive the appropriate number of kits to provide enough supplies until the Week 6 study visit to the investigational site. Each kit will bear a label describing the following 
information at a minimum: kit number, Spo nsor name, instructions for storage between 36°F and 
46°F (2°C and 8°C), and includes the statements “Caution: New Drug - Limited by [CONTACT_701338]” and “Keep out of reach of children.” 
6.2.3. Product Storage and Stability  
HTD1801 tablets should be stored at 2-[ADDRESS_952025] 2 hours before or after study medication. 
6.4.2. Prohibited Concomitant Medications  
[IP_ADDRESS]. Prohibited medications that are active against PBC 
Use of the following medications , active against PBC,  will be prohibited during the study from 
Baseline through 28 days after completion: 
UDCA 
Obeticholic acid  
Bezafibrate  
Fenofibrate It is important to emphasize that subjects will be counseled before starting investigational drug 
and at each visit not to take both UDCA and/or berberine  together with  HTD1801, as HTD1801 
contains both UDCA and berberine.  
[IP_ADDRESS]. Prohibited medications for the treatment of AIH  
 Use of medications for the treatment of AIH other than prednisone or azathioprine is prohibited 
(e.g., Mycophenolate).  
Stable use of immunosuppressives for other indications may be permitted (see 
above).   
[IP_ADDRESS]. Prohibited medications with potential for drug -drug interaction  
In addition, certain concomitant medications have been identified for exclusion from this proof-of-concep t study and are not to be taken at any time during the entire study (i.e., from Screening 
through Follow- Up). These exclusions are primarily due to the potential drug interaction profile 
of the BBR component of HTD1801. Table 2  lists medications known to be strong inhibitors of 
P glycoprotein (P-gp), CYP3A4, and CYP2D6; strong inducers of CYP3A4, as well as P-gp 
substrates with a narrow therapeutic index, and that are prohibited from concomitant use during this study. 
Supplements with potential for drug-drug interaction should be discussed with the medical 
monitor prior to enrolling a subject. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 29 Table 2: Prohibited M edication s with potential for drug -drug interaction   
Single Agents:  
P-glycoprotein  CYP3A4  CYP2D6  
Clarithromycin  Clarithromycin  Ritonavir  bupropi[INVESTIGATOR_701313]. John's wort  chloramphenicol  Quinidine  
Carvedilol  Itraconazole  Rifampin  Terbinafine  
Propafenone  Ketoconazole  Cobicistat   
Quinidine  Posaconazole  grapefruit juice   
Ranolazine  Voriconazole  conivaptan   
Verapamil  Atazanavir  Diltiazem   
Sildenafil  Boceprevir  Idelalisib   
Itraconazole  Darunavir  enzalutamide   
Ketoconazole  Indinavir  Mitotane   
Ritonavir  Lopi[INVESTIGATOR_701314]:  
P-glycoprotein  CYP3A4  
lopi[INVESTIGATOR_120870] (ombitasvir and/or dasabuvir)  
 saquinavir and ritonavir  
 tipranavir and ritonavir  
Source:  
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm0
[ZIP_CODE].htm (Tables 2- 2, 2-3, 3-2, 3-3, and 5 -2) 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 30 7. STUDY INTERVENTION DISCONTINUATION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1. Decrease in dose of study drug  
Subjects who have their dose of study drug decreased will be monitored closely with serum 
alkaline phosphatase, aminotransferases and bilirubin levels being measured every 2 to 4 weeks.  
Elevations in ALP or bilirubin will be promptly recognized by [CONTACT_7880] [INVESTIGATOR_701315].  If subjects are deemed to be treatment failures when their dose of study drug is decreased, study drug will be discontinued (see Section  7.2).  
7.2. Discontinuation of Study Intervention  
HTD1801 treatment must be discontinued for a subject if any of the following criteria are met. 
• Adverse event that may jeopardize subject’s safet y  
• Grade 3 and above adverse events (AEs) for which the causality is considered as related to investigational agent 
• Discontinuation due to drug-induced liver injury (refer to Section  10) 
• Request by [CONTACT_423] 
• Pregnancy  
For subjects who discontinue investigational study drug, an Early Termination Visit should be 
conducted at the time the investigational study drug is discontinued (see Section  7.3). Subjects 
who terminate from the study prior to Study Visit Week [ADDRESS_952026] the visit virtually and make use of a local laboratory for the study required Study Visit Week 16 lab tests.   
7.3. Participant Discontinuation/Withdrawal from the Study  
Subjects may be discontinued from the study for any of the following reasons: 
• Noncompliance 
o Failure to receive study medication or treatment  
o Failure to comply with protocol requirements 
o Unauthorized, subject-initiated changes in dosing regimen 
• Withdrawal of consent 
o Any subject who withdraws consent for any reason at any time during the 
study will be discontinued from the study, and the reason(s) will be 
documented on the appropriate eCRF page.  
• Lost to Follow- Up 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 31 o For subjects who cannot be contact[CONTACT_120907] a return for a scheduled clinic 
visit or for follow-up assessments as described, and who may be considered 
“lost to follow -up,” at least [ADDRESS_952027]’s last known address 
• Adverse Events   
o Study drug will be discontinued in an individual subject if the subject experiences a grade 3 and above adverse event (AE) for which the causality is considered as related to investigational study drug 
• Treatment Failure  
o If any subject fails treatment after  having their dose of HTD1801 reduced, 
their participation in the study will be ended and they will be allowed to 
resume their pre-study treatment for PBC.  A subject will be deemed to have 
failed treatment if serum ALP, after having been lowered on initia l treatment, 
returns to baseline or higher on two subsequent occasions (baseline being the average of the historical value and the value at screening).  
7.4.  Study Stoppi[INVESTIGATOR_701316] (grade 5 AE) or two subjects meeting the same grade 4 AE (life  threatening 
or disabling AE), or three subjects meeting the same grade 3 AE (severe AE), the trial will be 
paused and the AEs assessed for causality.  The event data will be submitted to the FDA with a 
request to resume conduct of the trial. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 32 8. STUDY PR OCEDURES  AND EVALUATIONS  
Study procedures are summarized across all scheduled study visits as indicated in the Study 
Schema (Section  1.2) and Table 1 Schedule of Activities (Section  1.3). Unscheduled visits may 
also occur at any time if medically warranted. Study related assessments performed at all visits 
will be recorded in the eCRF.    
Refer to Section  [ADDRESS_952028] is unable or unwilling to participate in an on- site visit du e to the COVID-19 
pandemic. 
8.1. Pre-screening (Days -56 to -28) ALP  
Prior to any clinical procedures and evaluations, written signed informed consent must be 
obtained.  If the historical ALP that was obtained as part of standard of care is not ≥1.[ADDRESS_952029] 28 days prior to full screening visit. 
•  Informed consent 
• Assign subject ID# 
• Chemistry sample for alkaline phosphatase 
8.2. Screening (Days -28 to -1) 
Screening procedures must be completed within [ADDRESS_952030] be conducted and assessments obtained.  The information will be collected in the investigational site’s standard source documents or in source document templates provided by [CONTACT_1034]. 
• Informed co nsent if not obtained at pre- screening visit  
• Confirm eligibility criteria  
• Demographic information 
• Medical history  
• Assign subject ID # if not obtained at pre-screening visit  
• Complete p hysical examination  
• Vital signs  
• Weight, height 
• Electrocardiogram, 12 lead (ECG) 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 33 • Serum chemistry panel  including GGT , Lipid panel -– fasting, unsweetened clear 
coffee, tea or water permitted but no food after supper the evening before 
• Complete blood count (CBC) with differential (no smear) 
• INR 
• Fibrinogen 
• CRP  
• Haptoglobulin 
• ELF 
• G6PD 
• IgM 
• IgG 
• AMA 
• ANA  
• TSH  
• FSH ( if needed to confirm menopausal status) 
• Pruritus VAS  
• Prior and concomitant medications 
Subjects will be instructed to stop all prohibited medications (see Section 6.4) prior to beginning 
Baseline procedures.   In particular, subjects will be cautioned against the use of UDCA until 
their participation in this study is complete.  
NOTE: If the screening ALP value is more than ≥30% lower than the historical value obtained as 
part of standard of care, the subject will not qualify for enrollment but may be re- screened as 
soon as 4 weeks later.  If on re -screening the ALP value continues to be >30% lower, the subject 
will not be inc luded in the study. 
8.3. Baseline /Day [ADDRESS_952031] met 
all the eligibility criteria (see Sections 5.1 and 5.2 ) will be eligible for enrollment in the study. 
Subjects will undergo the following Baseline procedures and assessments prior to the first dose of study drug:  
• Confirmation of continued eligibility  
• Update of medical history information  
• Targeted physical examination (to include assessment of only findings that were abnormal at Screening/Baseline visit and any new symptoms exhibited or volunteered by [CONTACT_1130]) 
• Vital signs  
• Weight  
• Serum chemistry panel  including GGT 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 34 • Lipid panel -– fasting, unsweetened clear coffee, tea or water permitted but no food 
after supper the evening before 
• CBC with differential 
• Fibrinogen 
• CRP  
• Haptoglobin 
• ELF 
• IGM  
• IgG 
• Bile acid panel  
• Urine p regnancy test for women of childbearing potential 
• GLOBE Score  (calculated by [CONTACT_701339], total 
bilirubin, alkaline phosphatase, albumin and platelet count) 
• Prurit us VAS  
• Adverse event monitoring 
• Concomitant medications  
• Dispense study drug 
8.4. Week 2  and Week 4 Visits (±3 days)  
Week 2 and Week 4 visits are conducted as in-clinic  visits or optional in -home  visits. The 
following procedures and assessments will be conducted at these visits: 
• Serum chemistry panel  including GGT 
• Adverse event monitoring 
• Concomitant medications  
Refer to Section  [ADDRESS_952032] is unable or unwilling to participate in an on- site visit du e to the COVID-19 
pandemic.  
8.5. Week 6  Visit (±3 days)  
The following procedures and assessments will be performed during the Week 6  clinic visit: 
• Targeted physical examination (to include assessment of only findings that were abnormal at Screening/Baseline visit and any new symptoms exhibited or volunteered by [CONTACT_1130]) 
• Vital signs  
• Weight  
• Serum chemistry panel  including GGT  
• Lipid panel - fasting, unsweetened clear coffee, tea or water permitted but no food after supper the evening before 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 35 • CBC with differential 
• INR 
• Fibrinogen 
• CRP  
• Haptoglobin 
• ELF 
• IGM  
• IgG 
• Bile acid panel  
• PK blood draw for at least  6 subjects who consent to participate in the PK sub-study 
o PK lab draw at -30 minutes prior to investigational study drug dosing 
o PK lab draw at ±[ADDRESS_952033] investigational study drug dosing 
o PK lab draw at ±[ADDRESS_952034] investigational study drug dosing 
• GLOBE Score  (calculated by [CONTACT_701339], total 
bilirubin, alkaline phosphatase, albumin and platelet count) 
• Prurit us VAS   
• Adverse event monitoring 
• Concomitant medications  
• Return study drug/reconciliation 
• Dispense study drug 
8.6. Week 8  Visit (±3 days)  
The Week 8 visit is  conducted as an in -clinic  visit or optional in -home lab  visit. The following 
procedures and assessments will be conducted at this visit: 
• Serum chemistry panel  including GGT 
• Adverse event monitoring 
• Concomit ant medications  
Refer to Section  [ADDRESS_952035] is unable or unwilling to participate in an on -site visit du e to the COVID-19 pandemic. 
8.7. Week 12  Visit (±3 days)  
The following procedures and assessments will be performed during the Week 12 clinic visit: 
• Targeted physical examination (to include assessment of only findings that were 
abnormal at Screening/Baseline visit and any new symptoms exhibited or volunteered 
by [CONTACT_1130]) 
• Vital signs  
• Weight  
• ECG  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 36 • Serum chemistry panel  including GGT 
• Lipid panel - fasting, unsweetened clear coffee, tea or water permitted but no food 
after su pper the evening before 
• CBC with differential 
• INR 
• Fibrinogen 
• CRP  
• Haptoglobin 
• ELF 
• IGM  
• IgG 
• Bile acid panel  
• PK blood draw for at least  6 subjects who consent to participate in the PK sub-study 
o PK lab draw at -30 minutes prior to investigational study drug dosing 
o PK lab draw at ±[ADDRESS_952036] investigational study drug dosing 
o PK lab draw at ±[ADDRESS_952037] investigational study drug dosing 
• Urine p regnancy test for women of childbearing potential 
• GLOBE Score  (calculated by [CONTACT_701340], total 
bilirubin, alkaline phosphatase, albumin and platelet count) 
• Prurit us VAS  
• Adverse event monitoring 
• Concomitant medications  
• Return study drug/reconciliation 
8.8. Week 16  Visit (±5 days)  
The final study visit will occur [ADDRESS_952038] dose of study drug at  a Week 16 follow-up 
visit. The Week 16 visit is conducted as an in- clinic visit or optional in -home lab visit. The 
following procedures and assessments will be conducted at this visit:  
• Study discharge 
• Targeted physical examination (to include assessment of only findings that were abnormal at Screening/Baseline visit and any new symptoms exhibited or volunteered by [CONTACT_1130]) 
• Vital signs  
• Weight  
Serum chemistry panel  including GGT 
• Adverse event monitoring 
• Concomitant medications  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952039] is unwilling or unable to attend the visit in person due to the COVID-19 pandemic: 
• Study discharge 
• Targeted physical examination (to include assessment of only findings that were 
abnormal at Screening/Baseline visit and any new symptoms exhibited or volunteered 
by [CONTACT_1130]) 
• Vital signs  
• Weight  
• ECG  
• Serum chemistry panel  including GGT  
• Lipid panel 
• CBC with differential 
• INR 
• Fibrinogen 
• CRP  
• Haptoglobin 
• ELF 
• IGM  
• IgG 
• Bile acid panel  
• Urine pregnancy test for women of childbearing potential 
• GLOBE Score  (calculated by [CONTACT_701341], total 
bilirubin, alkaline phosphatase, albumin and platelet count) 
• Pruritus VAS  
• Adverse event monitoring 
• Concomitant medications  
• Return  study drug/reconciliation 
Subjects who terminate from the study prior to Study Visit Week [ADDRESS_952040] 
available ALP result available prior to treatment with HTD1801 and change from baseline and 
percent change will be based upon this baseline value and the value as the respective timepoint. The binary ≥20% and ≥40% decrease endpoints will be based upon the percent change from 
baseline measure (did or did not have a percent change of this size). The normalization of ALP 
endpoint will be based upon the result and the associated normal range provided by [CONTACT_25699]. 
9.1.2. Secondary Efficacy Endpoints  
The seco ndary efficacy endpoints are each based upon laboratory results and the change from 
baseline of these results. As with the ALP endpoint baseline will be the last available pre -
treatment result, change from baseline will be based upon this baseline result and the result at the 
timepoints. Results will be assigned to timepoints based the timing of the result.  
9.2. Safety and Other Assessments  
9.2.1. Demographics and Medical History  
The Investigator or qualified designee will obtain demographic data, medical history, and medication history for each potential subject at Screening. Demographic data will include, at a 
minimum, the subject’s age and/or date of birth, sex, race, and ethnicity. Medical and medication 
history will include relevant medical conditions and treatments.  
9.2.2. Adverse Events  
Adverse events will be collected from the time at which the potential subject signs the ICF. 
Subjects will be instructed to report all AEs during the study and will be assessed for the 
occurrence of AEs throughout the study until at least 30 days after discontinuing the study drug. General and non-leading questions such as “How are you feeling?” should be asked when 
assessing the occurrence of AEs. The definition, reporting, and recording requirements for AEs 
are described in Section  9.3. 
9.2.3. Physical Examinations 
Physical examinations must be performed at investigational sites by [CONTACT_701342]. Abnormal physical examination findings that the 
Investigator considers clinically significant are to be reported as AEs if they began after the start of treatment and as medical history if they were present prior to treatment. 
The comprehensive physi cal examination will include the assessment of the following: skin; 
head, neck, eyes, ears, nose, throat; upper and lower extremities; chest and lungs; abdomen; 
cardiovascular system; and a brief neurological examination. The targeted physical examination 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952041]. Height (at Screening only) and weight will a lso be performed. Abnormal findings seen after the start of treatment  that the Investigator 
considers clinically significant are to be reported as AEs.  
9.2.5. Electrocardiograms  
Twelve- lead ECGs will be performed at the investigational site with the subject in a recumbent 
or semi -recumbent position after [ADDRESS_952042]’s treatment or management.  
9.2.6. Safety Related Laboratory Assessments 
A central laboratory will be utilized to perform safety related clinical la boratory assessments as 
specified in  the Schedule of Activities Table [ADDRESS_952043] eligibility at Screening and Baseline, as well as continued study participation for the duration of the study. Procedures for sample collection and handling will be detailed in the central laboratory manual and/or Study Procedures Manual ( SPM ). 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 40 Table 3 Laboratory Analytes 
Serum Chemistry  Hematology  Lipi[INVESTIGATOR_701317]:  
• Albumin  
• ALP  
• ALT  
• AST  
• Bicarbonate 
• Bilirubin, total 
• Bilirubin, direct  
• Blood urea nitrogen 
(BUN)  
• Calcium  
• Chloride  
• Creatinine  
• eGFR (calculated)  
• Creatine kinase 
• GGT  
• Glucose  
• Lactate dehydrogenase 
• Magnesium  
• Phosphorus  
• Potassium  
• Sodium  
• Total protein  
• Uric acid  Complete blood count, 
including:  
• Hemoglobin  
• Hematocrit  
• Platelet count 
• Red blood cell count  
• White blood cell count  
• Reticulocyte count  
 
White blood cell count 
differential, including:  
• Basophils  
• Eosinophils  
• Lymphocytes  
• Monocytes  
• Neutrophils  
 
Endocrinology:  
TSH  Total cholesterol  
LDL -c 
HDL -c 
Triglycerides  INR 
Other  
Fibrinogen  
CRP  
Haptoglobin  
ELF 
G6PD  
IgG 
IgM 
Bile acid s panel  
AMA ANA  
Serum and urine pregnancy 
tests 
FSH test  
9.2.7. GLOBE Score  
The GLOBE score is a validated risk assessment tool, able to accurately stratify PBC patients to 
high and low risk for future adverse events ( Lammers 2015). See Appendix A  and 
https://www.globalpbc.com/globe for details on calculating the GLOBE score.  While the 
variables that are used to calculate the GLOBE score are collected as part of the study 
assessments, actual calculation of the GLOBE score will be completed by [CONTACT_701343]. 
Although the GLOBE score calculation is a validated tool for subjects who have been on UDCA 
therapy for at least [ADDRESS_952044] been on UDCA for ≥[ADDRESS_952045] 6 months but <[ADDRESS_952046] 24 hours prior to their clinic visit (see Appendix B ). 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 41 9.2.9. Pharmacoki netic (PK) sub -study  
At least  6 subjects will be asked to participate in a PK sub-study to evaluate the plasma 
concentrations of UDCA and berberine.  Subjects who consent to participate in this sub-study 
will receive their dose of study drug in clinic and then provide one pre-dose (-30 minutes prior to 
dosing) and [ADDRESS_952047]-dose samples at 4 hours±30 minutes and at 8 hours±30 minutes at Study Visits W eeks 6 and 12.   
9.3. Adverse Events and Serious Adverse Events  
9.3.1. Definition of Adverse Event (AE)  
The following definition of an AE will be used for this study: Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. 
An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease (new or exacerbated) temporally associated with the use of the 
investigational product, regardless of whether it is considered to be related to the investigational 
product. 
The following are examples  of AEs:  
• Significant or unexpected worsening or exacerbation of the indication under study. 
• Exacerbation of a chronic or intermittent preexisting condition, including an increase 
in frequency or intensity of the condition. 
• New conditions detected or diagnosed after investigational product administration, even if they were present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected interaction with another medical product. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concurrent medication. 
Overdose should not be reported as an AE or serious adverse event (SAE), but rather the 
symptoms resulting from the overdose should be reported as such. 
Examples of AEs do not include the following: 
• Medical or surgical procedures (e.g., endoscopy, appendectomy). The medical 
condition that led to the procedure as the AE should be reported. 
• Situations that are unwanted by [CONTACT_701344], for example social inconvenience after admission to a hospi[INVESTIGATOR_307]. 
• Anticipated day -to-day fluctuations of a pre-existing disease or condition (present or 
detected before enrollment) that does not worsen overall. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 42 • Expected progression of the disease being studied, including signs or symptoms of 
the disease, unless progression is more severe than expected for the subject’s condition. 
Adverse events may include post- treatment events that occur as a result of protocol -mandated 
procedures (e.g., invasive procedures, modification of the subject’s previous therapeutic regimen).  
Adverse events should be captured even if they occur during periods without drug treatment, post-treatment periods, known placebo treatment, or in a reference or control group receiving drug or nondrug therapy. 
The Investigator is responsible for all AE assessments. The Investigator and investigational site 
staff will note all A Es mentioned by [CONTACT_610889], Baseline and during study drug 
administration. All clinical co mplaints volunteered by [CONTACT_701345]. The subject will receive appropriate treatment and medical supervision for any AE that occurs. 
All A Es judged to be clinically significant, including clinically significant laboratory 
abnormalities, will be followed until resolution. All A Es will be summarized in the clinical study 
report and the annual report or more frequently if requested by [CONTACT_61462]. Serious 
adverse events require special reporting in addition to documentation in the eCRF as described in Section  9.3.6. 
The severity of adverse events will be assessed according to Common Terminology C riteria for 
Adverse Events (CTCAE) version 5.0. 
(https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_refer
ence_5x7.pdf) 
9.3.2. Definition of Serious Adverse Even t (SAE)  
In this study, an SAE is defined as an AE that meets any of the following criteria: 
• Results in death. 
• Is life -threatening. The term life -threatening in the definition of an SAE refers to an 
event in which the subject was at risk of death at the tim e of the event. The term 
life-threatening does not refer to an event that, had it occurred in a more severe form, 
might have caused death.  
• Requires hospi[INVESTIGATOR_26109] a prolongation of an existing hospi[INVESTIGATOR_059]. In general, 
hospi[INVESTIGATOR_260048] t the subject has been detained at the hospi[INVESTIGATOR_701318]’s office or out-patient setting. Complications that occur during hospi[INVESTIGATOR_227926] A Es, but not necessari ly SAEs. A medical occurrence or 
complication that prolongs hospi[INVESTIGATOR_61375]. When there is doubt as to whether hospi[INVESTIGATOR_51956], the AE should be considered an SAE. Hospi[INVESTIGATOR_120874] a preexisting  condition that did not 
worsen from its original Baseline level is not considered an SAE. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 43 • A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions. This does not include AE s of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza 
and accidental trauma (e.g., sprained ankle) that may interfere or prevent everyday 
life functions but do not constitute a substantial disruption. 
• A congenital anomaly or birth defect. This refers to the offspring of a study subject. 
• Any other important medical event. Medical or scientific judgment should be 
exercised when deciding whether reporting is appropriate for other important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_701319]. These events should also be considered serious. Examples of such events are intensive treatment in an emergency room or at home for 
allergic bronchospasm, blood dyscrasias, or convulsions that do not result in 
hospi[INVESTIGATOR_512812]. 
An SAE requires additional detailed reports and follow-up. The content of these detailed reports 
must address the Investigator’s estimate of causality. The Medical Monitor will review the SAE 
to determine if it is an expected SAE (i.e., whether or not the SAE is identified in nature, severity, and frequency in the Investigator’s Brochure).  
9.3.3. Classification of an Adverse Event 
[IP_ADDRESS]. Severity of Event  
The Investigator will assess the severity for each AE and SAE reported during the study on the 
basis of his or her clinical judgment. Table 4 shows an overview of the severity classification as 
outlined in CTACE version 5.0.  For the purposes of assigning severity of each AE recorded in the source documentation and subsequently, in the eCRF , investigators are encouraged to refer to 
CTCAE v 5.0 for a more detailed description of any specific AE that may occur. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 44 Table 4 Classification of Adverse Events ( AEs) by [CONTACT_701346]  
(Grade 1)  Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
Moderate AE  
(Grade 2)  Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate instrumental activities of daily living
 
Severe AE  
(Grade 3)  Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self care activities of daily living
 
Life-threatening or 
disabling AE 
(Grade 4)  Life-threatening consequences; urgent intervention indicated.  
Death related to AE  
(Grade 5)  Death related to AE.  
 
a From Common Terminology Criteria for Adverse Events, Version 5.[ADDRESS_952048]. 
An AE that is assessed as severe should not be confused with an SAE. Severity is a category 
used for rating the intensity of an AE (such as mild, moderate, or severe myocardial infarction). However, an AE itself may be of relatively minor medical significance, such as a severe 
headache. Both AE s and SAEs can be assessed as severe. An AE is considered serious when it 
meets one of the predefined outcomes described in Section 9.3.2. 
[IP_ADDRESS]. Relationship to Study Intervention 
The Investigator must estimate the relationship between the investigational product and the 
occurrence of each AE or SAE by [CONTACT_512832]. Elements to consider 
for this estimate include the history of the underlying disease, concomitant therapy, other risk factors, and the temporal relationship of the AE or SAE to the investigational product. The 
Investigator will also consult the Investigator’s Brochure or product label for marketed products 
in estimating the relationship.  
Because of reporting timelines, the Investigator might have minimal information to include in the 
initial SAE report. However, the Investigator must always make an assessment of causality for 
every SAE before the transmission of the SAE report. The Investigator may change his or her opi[INVESTIGATOR_61380]-up information, with subsequent amendment of the 
SAE report. Causality assessment is a criterion used to determine regulatory reporting 
requirements and should not be left blank on the eCRF. The same applies to AE s that are to be 
processed as SAEs.  
Table 5 provides some definitions to use in the assessment. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 45 Table 5 Assessment of Causality of AEs 
Term  Definition  
Possibly related  The AE may be related to the investigational agent(s) or intervention: the AE 
has a temporal relationship to the administration of the investigational agent(s) 
or research intervention.  
Unrelated  
(or not related)  The AE is clearly not related to the investigatio nal agent(s) or intervention: the 
AE has no temporal relationship to the administration of the investigational agent(s) or research intervention, and follows no known or suspected pattern of response, and an alternative cause is present.  
[IP_ADDRESS]. Expectedness  
An expected AE is one that is consistent with the known risk information described in the 
product label (if applicable) or the current Investigator’s Brochure. The expectedness of an SAE 
will be assessed by [CONTACT_701347]. 
9.3.4. Time Period and Frequency for Event Assessment and Follow -Up 
AEs will be recorded starting after Screening  and at every visit through the Week [ADDRESS_952049]’s condition. All AEs and SAEs will be followed until the occurrence of one of the following: 
• The condition resolves. 
• The AE or SAE is not related. 
• The subject is lost to follow -up. 
• The subject is followed for 30 days after the End-of-Study Visit (or other appropriate time frame).  
• The subject starts another investigational product. 
9.3.5. Adverse Event Reporting  
When an AE or SAE occurs, the investigator is responsible for reviewing all documentation (e.g., hospi[INVESTIGATOR_1088], laboratory, and diagnostic reports) relative to the event(s). The investigator will record all relevant information about any AE (including SAEs) on the AE page 
of the eCRF. It is not acceptable for the investigator to send photocopi[INVESTIGATOR_9238]’s medical 
records in lieu of the properly completed AE or SAE pages of the eCRF. These documents should not be sent unless they are specifically requested by [CONTACT_603604]. If 
this request occurs, all subject identifiers and protected health information should be blinded on 
the copi[INVESTIGATOR_701320]. 
The investigator will also attempt to report a diagnosis, instead of signs, symptoms, or other 
clinical information, for the AE. The diagnosis, not the individual signs and symptoms, should be 
documented on the appropriate page of the eCRF as the AE or SAE. In addition, SAEs need to 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952050] be reported to the Sponsor’s or 
designee’s pharmacovigilance department by [CONTACT_648], fax, or e- mail within 24  hours of the 
time the Investigator becomes aware of the SAE ( Table 6). Any SAE reported by [CONTACT_701348]. Urgent reporting of SAEs is required for the following reasons: 
a. To enable the Sponsor to fulfill the reporting requirements to the appropriate 
regulatory authority 
b. To facilitate discussion between the Sponsor and the Investigator about appropriate follow- up measures (if necessary)  
c. To facilitate the Sponsor’s rapid dissemination of information about AEs to other investigators or sites in a multicenter study  
d. To facilitate reportin g unanticipated problems involving risk to subjects to the 
institutional review board (IRB) or independent ethics committee (IEC).  
Table 6 Timeline for Reporting SAEs  
Initial SAE Report  Follow -up SAE Report  
Time Frame  Documents  Time Frame  Documents  
24 hours SAE report  7 days Updated SAE report 
The SAE report will be completed as thoroughly as possible, including the following: 
• Subject identification information  
• Event term  
• All available details about the SAE  
• Causality of each SAE  
• Signature [CONTACT_701359]’s or designee’s pharmacovigilance department 
within the designated time frames. If additional information to complete the SAE report is 
needed, the Investigator will not wait before notifying the pharmacovigilance department of the 
SAE. The SAE report will be updated by [CONTACT_701349].  
9.3.7. Reporting Events to Participants  
Subjects will be given any new information that is learned about the study drug, or about their condition, during the course of the research study that might affect their willingness to continue participation. Subjects  will be told about any new risks that become known during this research 
study. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952051]  
[IP_ADDRESS]. Gastrointestinal Event 
Subjects taking HTD1801 may experience GI  discomfort related to this therapy. This is variously 
described as diarrhea, abdominal bloating, abdominal discomfort, abdominal pain, and 
sometimes even constipation. Rather than have the subject discontinue and stop treatment altogether, downward dose titration from the starting dose of HTD1801 2000 mg per day is allowed and even encouraged.  
Guidelines for dose reduction in the event of GI discomfort are outlined i n Section 6.1.3. 
[IP_ADDRESS]. Treatment Failure due to HTD1801 Dose Reduction  
If any subject with PBC fails treatment after having their dose reduced, their study participation 
will be terminated and the subject would be able to resume their pre-study treatment for PBC 
after early termination study -required assessments completed.  A subject will be considered to 
have failed treatment if the serum ALP, after having been lowered on treatment, returns to baseline or higher on two subsequent assessments (baseline is calculated as the average of the 
historical value and the value at screening). 
[IP_ADDRESS]. Reporting of Pregnancy 
When any member of the study staff becomes aware of a subject’s (or subject’s partner’s) 
pregnancy, the site staff must report the pregnancy to the medical monitor and the within [ADDRESS_952052] will discontinue study medication. The pregnancy will be followed until there is an outcome and the outcome is reported to the sponsor. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 48 10. DRUG -INDUCED LIVER INJURY (DILI) MONITORING AND 
STOPPI[INVESTIGATOR_701321]-induced liver injury and to educate 
subjects to recognize DILI symptoms and seek immediate medical attention.  
Liver enzymes and serum bilirubin levels will be assessed at each clinic visit.  Elevated ALTs 
will be assessed and dealt with as shown in Table [ADDRESS_952053] normal or near normal ALT levels 
at baseline.  The Medpace Reference Laboratory (MRL) which will serve as the central laboratory for this study has defined its upper limit of normal for ALT as 53 U/L, in both males 
and females.  The study therefore considers up to 60 U/L as being normal or near normal while 
>60 U/L is considered elevated.  
Persistent Cholestatic liver injury is characterized by [CONTACT_701350]/or bilirubin (see Table 7 and Table 8 ). 
10.1. Protocol Definition of Normal or Near Normal and Elevated ALT  
10.1.1. Detection of Potential DILI in Subjects with Normal or Near Normal ALT levels 
at baseline 
Because some subjects with PBC may have normal or near normal ALT levels at baseline (see Hirschfield 2015), an on-treatment ALT value more than 3x the ULN (i.e. >180 u/L) will be the threshold for triggering the DILI monitoring plan for these subjects. 
10.1.2. Detection of Potential DILI in Subjects with Elevated ALT levels at baseline 
Because subjects to be enrolled in the study have underlying liver disease, it is very likely that 
they may have an elevated ALT level at baseline and therefore multiple s of the baseline will be 
used for DILI monitoring where the baseline value is elevated.   The baseline ALT value will be 
calculated as the average of those obtained at the screening and baseline visits.   An on- treatment 
ALT value more than 3x the baseline value will be the threshold for triggering the DILI monitoring plan for these subjects. 
10.1.3. Process for DILI Monitoring  
Serum ALT will be measured as part of a serum chemistry panel at screening, baseline and at 
weeks 2, 4, 6, [ADDRESS_952054] the clinical site to initiate 
the DILI monitoring protocol.   
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 49 Table 7: Liver Monitoring Procedure – For Subjects with Normal or Near Normal Baseline ALT ( ≤60 U /L) 
Event  Observation  Action  
ALT becomes 
elevated  Isolated increase in ALT to ≥3x ULN (i.e., ≥180 /L) with no 
increase in serum bilirubin and presence of symptoms of anorexia, 
nausea, fatigue, right upper abdominal discomfort or vomiting 
preceding or following the isolated increase in ALT to ≥3x ULN.  • Promp tly repeat serum chemistry panel (ALT, AST, ALP, total bilirubin and 
direct bilirubin) within 2 to 5 days* 
• If subject lives remotely from the site, local labs may be obtained   
• The PI [INVESTIGATOR_701322]  
• Continue investigational study drug  
ALT remains 
elevated  If ALT remains ≥3x ULN  • Obtain serum chemistry panel (as above) and repeat 2 – 3 x/week until stable  
• Frequency of testing can be decreased to once per week or less if abnormalities 
stabilize or the subject is asymptomatic  
• Obtain detailed history of symptoms and prior or concurrent medical history  
• Obtain history of concomitant drug use including non- prescription 
medications, herbal & dietary preparations, alcohol use, recreational drug use, 
and special diets  
• Where appropriate, rule out acute viral hepatitis  types A, B, C, D, & E, 
autoimmune or alcoholic hepatitis, NASH, hypoxic/ischemic hepatopathy & biliary tract disease  
• Obtain a history of exposure to environmental chemical agents  
• Obtain additional tests to evaluate liver function, as appropriate (e.g., IN R, 
CBC with differential)  
• Continue investigational study drug  
ALT decreases  ALT return to <3x ULN or baseline level  • Resume study -required laboratory assessments as per the Summary of Events 
table and continue investigational study drug  
Elevated Liver 
Function Tests Worsen or Clinical 
Symptoms 
Develop  If ALT is >8x ULN of baseline on one occasion, or  
If ALT is >5x ULN of baseline for more than 2 weeks, or  
If ALT is >3x ULN of baseline AND bilirubin is >2X ULN OR 
INR >1.5), or  • Permanently STOP  investigational study drug  
• Continue monitoring until all abnormalities return to normal or to the baseline 
state 
• All DILI monitoring results must be recorded in the DILI monitoring eCRF  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 50 * The PI [INVESTIGATOR_701323].  Local lab results must be entered into an unsc heduled visit within the EDC  If ALT is >3x ULN of  baseline AND subject is symptomatic 
(severe fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash, and/or eosinophilia (>5%)  
Persistent 
Cholestatic Liver 
Injury  If serum ALP is >2x ULN and total and direct bilirubin is >2x ULN  • Permanently STOP  investigational study drug  
• Cont inue monitoring until all abnormalities return to normal or to the baseline 
state 
• All DILI monitoring results must be recorded in the DILI monitoring eCRF  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 51 Table 8: Liver Monitoring Procedure – For Subjects with Calculated Baseline ALT >60 U/L (Elevated ALT) 
Event  Observation  Action  
ALT becomes 
elevated  Isolated increase in ALT to ≥3x ULN (i.e. , ≥180 u/L) with no 
increase in serum bilirubin and presence of symptoms of anorexia, nausea, fatigue, right upper abdominal discomfort or vomiting  
preceding or following the isolated increase in ALT to >3x ULN.  • Promptly r epeat serum chemistry panel (ALT, AS T, ALP, total bilirubin and 
direct bilirubin) within 2 to 5 days* 
• If subject lives remotely from the site, local labs may be obtained   
• The PI [INVESTIGATOR_701324]  
• Continue investigational study drug  
ALT remains 
elevated  If ALT remains ≥3x calculated baseline • Obtain serum chemistry panel (as above) and repeat 2 – 3 x/week until stable  
• Frequency of testing can be decreased to once per week or less if abnormalities 
stabilize or the subject is asymptomatic  
• Obtain detailed history of symptoms and prior or concurrent medical history  
• Obtain history of concomitant drug use including non- prescription 
medications, herbal & dietary preparations, alcohol use, recreational drug use, 
and special diets.  
• Where appropriate, rule out acute viral hepatitis types A, B, C, D, & E, autoimmune or alcoholic hepatitis, NASH, hypoxic/ischemic hepatopathy & biliary tract disease  
• Obtain a history of exposure to environmental che mical agents  
• Obtain additional tests to evaluate liver function, as appropriate (e.g., INR, CBC with differential)  
• Continue investigational study drug  
ALT decreases  ALT return to <3x ULN or baseline level  • Resume study -required laboratory assessments as per the Summary of Events 
table and continue investigational study drug  
Elevated Liver 
Function Tests 
Worsen  If ALT is >8x ULN of calculated baseline on one occasion, or  
If ALT is >5x ULN of calculated baseline for more than 2 weeks, or  
If ALT is >3x ULN of calculated baseline AND bilirubin is >2X 
ULN OR INR >1.5), or  • Permanently STOP  investigational study drug  
• Continue monitoring until all abnormalities return to normal or to the calculated baseline state 
• All DILI monitoring results must be recorded in the DILI monitoring eCRF  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 52 * The PI [INVESTIGATOR_701323].  Local lab results must be entered into an unscheduled visit within the EDC  If ALT is >3x ULN of calculated baseline AND subject is 
symptomatic (severe fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophili a (>5%)  
Persistent 
Cholestatic Liver 
Injury  If serum ALP is >2x ULN and total and direct bilirubin is >2x ULN  • Permanently STOP  investigational study drug  
• Continue monitoring until all abnormalities return to normal or to the calculated baseline state 
• All DILI monitoring results must be record ed in the DILI monitoring eCRF  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952055] from quarantine restrictions, site closures and travel restrictions may limit 
the site’s and subject’s capability to have on- site visits .  
11.2. Operational Contingencies related to COVID -[ADDRESS_952056] to  occur via a remote visit by [CONTACT_16062] a video conference, 
per site practice and procedures, to assess changes in the subjects’ health condition, make note of 
any changes in concomitant medications, and inquire about adverse events. The visit must be documented as a telephone/video conference visit with arrangements for laboratory assessments.  
The site will enter the laboratory results, if obtained at a local laboratory, into the EDC as an “unscheduled” visit that will be mapped to the specific visit for  which local laboratory data were 
obtained.  If the visit specific blood draw is obtained by [CONTACT_701351], it will be shipped to the central laboratory; the results will be entered into the central laboratory database and merged with the clinical database at the completion of the study.  
Every effort must be made to complete the full scope of the study visit activities and procedures. Any deviation from the procedures and protocol-specified contingency measures due to COVID-[ADDRESS_952057] accountability.  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 54 12. STATISTICAL CONSIDERATIONS  
12.1. Statistical Hypotheses  
The primary hypothesi s for t his study is that treatment with HTD1801 results in reductions in 
ALP:  
𝐻𝐻0:𝐴𝐴𝐴𝐴𝐴𝐴𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊  12− 𝐴𝐴𝐴𝐴𝐴𝐴𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊
𝐴𝐴𝐴𝐴𝐴𝐴𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊 ≥0 𝑣𝑣𝑣𝑣 .  𝐻𝐻𝐵𝐵:𝐴𝐴𝐴𝐴𝐴𝐴𝑊𝑊𝑊𝑊𝑊𝑊𝑊𝑊  12− 𝐴𝐴𝐴𝐴𝐴𝐴𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊
𝐴𝐴𝐴𝐴𝐴𝐴𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊𝐵𝐵𝐵𝐵𝐵𝐵𝑊𝑊< 0 
The estimand will be the percent change from baseline and will be measured within all subjects 
on treatment and who provide data at Week 12. This estimand is similar to the While on 
Treatment Strategy outlined in ICH e9 R1 but is limited to on treatment results at Week 12 (i.e. , 
results from  prior to Week 12 are not included in the analysis of the Week 12 results). 
Testing will be one sided using a 5% alpha level. 
12.2. Sample Size Determination  
A sample size of 30 subjects provides ≥90% power for the primary endpoint assuming a mean 
percent reduct ion in ALP of 15% and a SD of 25%. Power calculations use a 5% one sided alpha 
and a t -test. Sample size calculation were performed in PASS  (PASS 2014). 
12.3. Populations for Analyses  
The following analysis populations will be defined for statistical analysis: 
• Screened population 
o The Screened population will consist of all subjects who sign the study informed 
consent. 
• Intention- to-treat (ITT) population  
o The ITT population will consist of all subjects that receive at least one dose of 
HTD1801. This population will be used for all efficacy, safety, and baseline/demographic analyses and summaries.  
• Population undergoing pharmacokinetic testing 
o At least 6 subjects will undergo sparse PK sampling at weeks 6 and 12. 
12.4. Statistical Analyses  
12.4.1. General Approach  
Endpoints will be summarized using descriptive statistics. For continuous variables n (number of subjects with data), mean, standard deviation, median, minimum, and maximum will be used. 
For categorical results the number of subjects and the percent of subjects per category will be 
summarized. Confidence intervals will be generally reported using 95% two- sided confidence 
intervals. When testing is used p-values with four decimal places will be reported; no adjustment 
for multiplicity will be conducted.  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 55 Missing data will not be imputed for the efficacy analyses. Missing dates for adverse events and 
concomitant medic ation will be imputed to allow these items to be summarized  as on or off 
treatment.  
12.4.2. Analysis of the Primary Efficacy Endpoint(s) 
Alkaline phosphatase levels , change from baseline, and percent change from baseline will be 
summarized with descriptive statistics and 95% normal approximation confidence intervals. 
Testing for the percent change endpoint using a t- test will also be performed. Given the limited 
sample size (i.e. less than 30 subjects) and the potential for right skewed data the normality 
assumption may not be fully accurate. Hence, the true alpha level may theoretically not be 5%. 
As such, these tests will be considered descriptive more than confirmatory. 
12.4.3. Analysis of the Secondary Endpoint(s)  
The secondary endpoints including the secondary ALP endpoints will be summarized using 
descriptive statistics. Summary statistics at each timepoint that data is captured will be provided 
for the result as well as the change from baseline, when change from baseline is applicable. Confidence intervals will be produced for changes in serum bilirubin and change in gamma-glutamyl transferase.  
12.4.4. Safety Analyses 
Safety endpoints will be summarized using descriptive statistics.  
Treatment emergent adverse events (TEAE), events that start on or after the start of treatment, 
will be summarized by [CONTACT_428801] m. Summaries of all TEAEs, 
treatment emergent SAEs, related TEAEs and TEAEs by [CONTACT_701352].  
Laboratory, vital sign, and ECG results will be summarized as continuous measures (e.g., change from baseline). Selected laboratory results will also be summarized as categorical variables (e.g., 
‘in’ versus ‘out’ of the normal range).  
12.4.5. Pharamacokinetic Analyses 
Descriptive statistics will be summarized for plasma concentrations of BBR and UDCA as a 
function of study visit.  These concentrations will be used to build a population PK model in 
combination with PK data from other studies to inform model- derived parameters, if applicable.  
12.4.6. Baseline Descriptive Statistics  
Subjects who discontinue treatment or withdraw from the study, and the reasons for doing so, will be summarized. Subject demographic and baseline characteristics will be summarized.  
12.4.7. Planned Interim Analyses  
Enrollment into the study may be stopped early prior to enrollment of 30 subjects should the scientific goal (evaluate the effects of HTD1801 on serum ALP ) of the study be achieved with 
the currently available data. That is, if prior to enrollment of [ADDRESS_952058] (or the subject’s legally acceptable representative) before 
performing any study-specific Screening or Baseline evaluations. One copy of the signed ICF 
and authorization for use and disclosure of protected health information form will be given to the subject, and the Investigator will retain the original. The ICF and authorization for use and 
disclosure of protected health information, which is prepared by [CONTACT_701353], must have been reviewed and approved by [CONTACT_1034], the Study Monitor, and the Investigator’s IRB or IEC and privacy board (if separa te from the IRB/IEC) before the 
initiation of the study. The ICF must contain the [ADDRESS_952059] contain the elements required by [CONTACT_1641] 45 of the Code of Federal Regulations, Section 164.508(b), and any local regulations for valid authorizations. 
13.2. Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_701354]. If the study is prematurely terminated or suspended, the Principal 
Investigator [INVESTIGATOR_112578], the Institutional Review Board (IRB), and sponsor and will provide the reason(s) for the termination or suspension. Study participants will be contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
• Determination of unexpected, significant, or unacceptable risk to participants 
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]  
• Insufficie nt compliance to protocol requirements 
• Data that are not sufficiently complete and/or evaluable 
• Determination that the primary endpoint has been met 
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, and data qualit y are 
addressed, and satisfy the sponsor, IRB and/or Food and Drug Administration (FDA). 
13.3. Study Documentation  
13.3.1. Investigator Information  
Investigator information is included in the SPM (or other applicable instructions), which is 
updated as needed. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 57 13.3.2. Investigator’s Study Files 
Documentation about the Investigator and his/her study staff, the IRB/IEC, and the institution is 
required before site initiation. Copi[INVESTIGATOR_701325], along with the following supplemental information: a list of Investigator’s obligations; the Investigator’s Brochure; the clinical protocol and amendments; 
safety information; information about the investigational product, biological samples, and the 
applicab le laboratory(ies); the SPM (or other applicable instructions) and study logs; eCRFs; 
records of monitoring activities; and correspondence between the Sponsor or Study Monitor and the Investigator. 
13.3.3. Case Report Forms and Source Documentation  
The Investigat or must make study data accessible to the Study Monitor, other authorized 
representatives of the Sponsor, and the appropriate regulatory authority inspectors. The eCRF for 
each subject will be checked against source documents at the investigational site by [CONTACT_153670], and a final copy of the eCRF will be signed by [CONTACT_701355]. A copy of the final eCRFs will be provided to the Investigator in PDF format on computer disc after study closure to be kept in the Investigator’s study files. 
13.3.4. Retention of Study Documents  
According to ICH E6, Section 4.9, all eCRFs, as well as supporting paper and electronic source 
documentation and administrative records, must be retained by [CONTACT_31201] [ADDRESS_952060]’s electronic records to which they pertain. The Investigator must retain either the originals of the audit trails or a certified copy of the audit trails.  
13.4. Confidentiality  
13.4.1. Data  
The Investigator must keep all information confidential about the nature of the proposed investigation provided by [CONTACT_331607] (with the exception of 
information required by [CONTACT_61475]/IEC, the subject, or the 
appropriate regulatory authority). 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952061] (e.g., the signed ICF) must be maintained in strict 
confidence by [CONTACT_737], except to the extent necessary to allow auditing by [CONTACT_701356], the Study Monitor, or Sponsor representatives. 
13.5. Protocol Compliance  
Substantive changes in the protocol include changes that affect the safety of subjects or changes 
that alter the scope of the investigation, the scientific quality of the study, the experimental 
design, dosages, assessment variable(s), the number of subjects treated, or the subject- selection 
criteria. Such changes must be prepared as a protocol amendment by [CONTACT_512841]. A protocol 
amendment must receive IRB/IEC approval before implementation. In parallel with the IRB/IEC approval process, the protocol amendment will be submitted to the appropriate regulatory 
authority as an amendment to the regulatory submission under which the study is being 
conducted. If a protocol amendment requires changes in the ICF, the revised ICF prepared by [CONTACT_701357], Study Monitor, and the IRB/IEC before implementation.  
Departures from the pro tocol eligibility criteria (see Sections 5.1 and 5.2) are not permitted as 
these could jeopardize subject safety, study integrity, or regulatory acceptance of the results. 
Departures from other protocol procedures or requirements are allowed only in situations that 
eliminate an immediate risk to a subject and that are deemed crucial for the safety and wellbeing 
of that subject. The Investigator or the attending physician will also contact [CONTACT_701358] a departure. These departures do not require pre- approval 
by [CONTACT_1201]/IEC; however, the IRB/IEC and Medical Monitor must be notified in writing as soon 
as possible after the departure has been made. In addition, the Investigator will document in the subject’s eCRF the reasons for the protocol deviation and the ensuing events. 
13.6. Study Monitor Functions and Responsibility  
The Study Monitor, in accordance with the Sponsor’s requirements, will ensure that the study is conducted and documented properly by [CONTACT_61480] E6, Section 5.18.4. 
13.7. Quality Assurance and Quality Control  
Each clinical site will perform internal quality management of study conduct, data and biological specimen collection, documentation and completion. 
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data 
anomalies will be communicated to the site(s) for clarification/resolution.  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952062] Operating Procedures (SOPs), the monitors will verify that the 
clinical trial is conducted and data are generated and biological specimens are collected, 
documented (recorded), and reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482]. 
13.8. General Information  
The Investigator should refer to the Investigator’s Brochure, SPM (or other applicable instructions), and any other information provided about the investigational product and details of the procedures to be followed during this study. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 [ADDRESS_952063]  upper limit of normal  
VAS  visual analogue scale  
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 62 15. REFERENCES 
Bahar R, Wong KA, Liu CH, Bowlus CL. Update on new drugs and those in development for the 
treatment of primary biliary cholangitis. Gastroenterol Hepatol (NY) . 2018;14(3):154-163. 
Chalasani N, Regev A.  Drug-induced liver injury in patients with preexisting chronic liver 
disease in drug development:  How to identify and manage.  Gastroenterology 2016;151:1046-1051. 
Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxychol ic acid 
therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology . 2000;32(6):1196-
1199. 
Di Bisceglie AM, Watts GF, Lavin P, Yu M, Bai R, Liu L.  Pharmacokinetics and 
pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with 
hyperlipi[INVESTIGATOR_035] .  Lipi[INVESTIGATOR_632399].  2020;19:239 https://doi.org/10.1186/s12944-
020-[ZIP_CODE]-4. 
Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Di Bisceglie AM.  A Phase 2a, Randomized 
Controlled Trial of Berberine Ursodeoxycholate (BUDC) in Patients with Presumed Non-
Alcoholic Steatohepatitis (NASH) and Type 2 Diabetes.  Hepatology 2020:721(suppl):1007A.  
Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary 
biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterol . 2015;148:751-
761. 
https://www.fda.gov/regulatory- information/search -fda-guidance -documents/drug-induced- liver-
premarketing -clinical -evaluation   
Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring 
system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic 
acid therapy. Gastroenterol . 2015;149(7):1804-1812. 
Levy C, Lindor KD. Treatment Options for Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Curr Treat Options Gastroenterol . 2003;6(2):93-103. 
Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from 
the American Association for the Study of Liver Diseases. Hepatology . 2019;69(1):394-419. 
Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER. Effects of 
ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology . 
1996;110(5):1515-1518. 
OCALIVA (obeticholic acid) tablets [package insert]. [LOCATION_001], NY. Intercept 
Pharmaceuticals, Inc. 20 20. 
PASS 13 Power Analysis and Sample Size Software (2014). NCSS, LLC. Kaysville, Utah, [LOCATION_003], ncss.com/software/pass.  
URSO 250 and URSO Forte (ursodiol) tablets [package insert]. Bridgewater, NJ. Aptalis Pharma 
US, Inc. 2013. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 63 APPENDIX  A. GLOBE SCORE  
https://www.globalpbc.com/globe  
The GLOBE score for patients with Primary Biliary Cholangitis 
(PBC)  
The GLOBE score is an internationally relevant and validated risk assessment tool, able to accurately 
stratify PBC patients to high and low risk. 
Age, years  
at initiation of UDCA t herapy  
     
Total bilirubin level , µmol/L or 
mg/dl  
after one year of UDCA therapy  
 Upper limit of 
normal: 
 
Alkaline phosphatase level , U/L  
after one year of UDCA therapy  
 Upper limit of 
normal: 
 
Albumin , g/L  
after one year of UDCA therapy  
 Lower limit of 
normal: 
 
Platelets , x 109/L 
after one year of UDCA therapy  
     
  
Interpretation of the GLOBE score:  
Patients with a GLOBE score corresponding with an estimated transplant -free survival 
comparable with an age - and sex -matched population are at low risk for future adverse events 
and patients with a GLOBE score corresponding with a transplant -free survival that significantly 
deviates from an age - and sex -matched population may benefit from new therapi[INVESTIGATOR_701326] - and sex -matched population, a population with a life- expectancy comparable 
with that of other countries participating in the Global PBC Study Group, were retrieved from a 
Dutch registry (Statistics Netherlands, www.cbs.nl).   
The GLOBE score uses age -specific thresholds beyond which survival significantly deviates 
from an age - and sex matched general population. In subgroups of patients aged 66 years, age-
specific GLOBE -score thresholds beyond which survival significantly deviates from matched 
individuals are 0.52, 0.01, 0.60, 1.01 and 1.69, respectively. 
CONFIDENTIAL  HighTide Biopharma Pty. Ltd. 
Clinical Protocol  Study HTD1801.PCT013 
 64 APPENDIX  B. PRURITUS VAS SCORE  
 
 
http://www.pruritussymposium.de/visualanaloguescale.html 
 
Scoring:  
VAS 0=  No pruritus 
VAS < 3=  Mild pruritus 
VAS ≥ 3 -<7= Moderate pruritus  
VAS ≥ 7 -<9 = Severe pruritus 
VAS ≥ 9= Very severe pruritus  
 
